Because the IL-6 and JAK-STAT pathways were among the top upregulated pathways in participants with LC in both the 2020–2021 and the 2023–2024 cohorts, we have initiated a clinical trial to evaluate the therapeutic efficacy of the JAK1 inhibitor abrocitinib for LC (NCT06597396). Here, JAK1 is linked to laryngotracheoesophageal cleft.